Cidara Therapeutics to Present at the H.C. Wainwright Conference
Cidara Therapeutics, Inc. (Nasdaq: CDTX) is preparing for a significant presentation at the H.C. Wainwright 26th Annual Global Investment Conference. This biotechnology company is recognized for its cutting-edge approach to developing drug-Fc conjugate (DFC) immunotherapies, utilizing its proprietary Cloudbreak platform. Dr. Jeffrey Stein, the President and CEO, will provide valuable insights into their pioneering work aimed at improving treatment options for serious diseases.
Event Details
The highly anticipated presentation is scheduled for:
Event: H.C. Wainwright 26th Annual Global Conference
Date: Monday, September 9, 2024
Time: 7:00 am ET
Starting from the specified date and time, Cidara's presentation will be available on-demand in the investor section of the company’s official website. This presents an excellent opportunity for stakeholders to gain insights into Cidara's progress and future plans.
About Cidara Therapeutics
With a strong emphasis on developing innovative drug-Fc conjugates, Cidara Therapeutics is making remarkable progress in the pharmaceutical industry. Their leading candidate, CD388, aims to offer long-lasting antiviral prevention against both seasonal and pandemic influenza, presenting a single-dose solution. Recently, CD388 received Fast Track Designation from the FDA, and Cidara is set to launch a Phase 2b clinical trial for this antiviral ahead of the upcoming flu season in 2024.
Innovative Approaches in Oncology
Beyond their virology efforts, Cidara is also extending its DFC platform into the field of oncology. They have recently obtained an Investigational New Drug (IND) allowance for CBO421, which targets CD73 in solid tumors. This development underscores their commitment to creating targeted cancer therapies, thereby enriching the company’s diverse portfolio.
Cidara's Commitment to Patients
Based in San Diego, Cidara Therapeutics is devoted to revolutionizing patient care through its innovative therapies. By concentrating on diseases with significant unmet needs, Cidara strives to enhance patient outcomes and improve quality of life through advanced science and technology.
Looking Ahead
As Cidara prepares for its presentation at this esteemed conference, the insights shared are likely to influence investor perspectives and stakeholder engagement. The advancements in therapeutics, particularly with the promising candidates CD388 and CBO421, are expected to generate interest and support for Cidara’s ongoing research and development efforts.
Frequently Asked Questions
What is Cidara Therapeutics known for?
Cidara Therapeutics specializes in developing innovative drug-Fc conjugate immunotherapies that aim to enhance treatment outcomes for serious diseases.
Who will be presenting at the H.C. Wainwright Conference?
Dr. Jeffrey Stein, the President and CEO of Cidara Therapeutics, will be the featured speaker at the event.
What is the main focus of Cidara's lead candidate, CD388?
CD388 is designed to serve as a long-acting antiviral for the prevention of seasonal and pandemic influenza, requiring only a single administration.
What recent milestones have Cidara achieved?
Cidara's CD388 recently received Fast Track Designation from the FDA, highlighting its potential and paving the way for a Phase 2b trial.
Where is Cidara Therapeutics headquartered?
Cidara Therapeutics is located in San Diego, California, where it conducts its innovative research and development activities.
